NEW YORK –Single-cell proteomics firm IsoPlexis said Thursday that it is partnering with Yale University to develop assays for COVID-19 using the company's IsoLight system.
According to the company, the partners aim to identify markers of patient immune response to the virus that could be used to inform development of therapies and vaccines for the disease.
"We are looking forward to utilizing the IsoLight's unique ability to functionally phenotype each immune cell in patients with COVID-19 for more than 30 effector functions simultaneously, providing a comprehensive picture and the direct evidence of antiviral immune activation or immune-mediated hyperinflammatory pathology that is impossible with other technologies," Yale Professor Rong Fan, the lead investigator of the study, said in a statement.
Fan is a co-founder of IsoPlexis as well as the chair of its scientific advisory board.
"This work will provide critical functional insights into the mechanisms of various immune responses to COVID," said IsoPlexis CEO Sean Mackay. "Through the identification of novel rapid circulating markers, we hope to help accelerate the development of critical therapeutics and vaccines."